Relmada Therapeutics, Inc. (RLMD) Q4 2024 Annual Earnings
RLMD·Reported March 27, 2025·After market close
Diluted EPS came in at $-0.62, beat the $-0.70 consensus by $0.08.
Diluted EPS
$-0.62beat by $0.08
Consensus: $-0.70
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Relmada Therapeutics, Inc.'s Q4 2024 earnings report.
Relmada Therapeutics, Inc. (RLMD) reported Q4 2024 earnings on March 27, 2025 after market close.
Relmada Therapeutics, Inc. reported diluted EPS of $-0.62 for Q4 2024.
EPS beat the consensus estimate of $-0.70 by $0.08.
You can read the 10-K periodic report (0001013762-25-003426) directly on SEC EDGAR. The filing index links above go to sec.gov.